Adverse events and patient compliance
hepatic decompensation
ADVERSE EVENT, UPPER GASTROINTESTINAL BLEEDING
There was no patient experienced major adverse event during the study. One patient temporarily discontinued BCAA for 1 week during hospital admission because of non-PHT related upper gastrointestinal bleeding at week 9 of the study. The rest of participants reported > 90% compliance to the study medications. None was documented with a new episode of hepatic decompensation during the study.